Moderna 2022 Priorities and Capital Allocation

By the end of 2Q22, we will have started three pivotal, Phase 3 trials within approximately one year of an IND being opened COVID- 19 vaccine RSV vaccine IND opened Ph 3 started Efficacy readout 5 months March '20 July '20 Nov '20 Older adults added to Ph 1 Jan '21 Ph 3 started Seasonal efficacy endpoint 13 months Feb '22 IND opened Ph 3 expected to start Immunogenicity endpoint Flu vaccine ~12 months June '21 2Q '22 Slide 24 1. Research Synthesis: Time and Success Rates of Pharmaceutical R&D, https://www.knowledgeportalia.org/r-d-time-success mRNA vaccine technology is de-risked; pursuing parallel clinical development that is significantly faster than industry standard¹ Moderna's mRNA vaccines Use the same mRNA chemistry, same LNP and same manufacturing platform moderna

View entire presentation